Revolution Medicines, Inc. - 8-K Filing
Revolution Medicines reports Q3 2026 net product revenue of $197.6 million following U.S. launch of RASONQUE for metastatic pancreatic cancer. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $RVMD
Read the full article at SEC EDGAR
Part of the story Upland Software Outlines Long-Term Path to 35% Adjusted EBITDA Margin and Revenue Stabilization (7 articles)